Clinical trials: Ebola Virus Infection
Cataract
PREVAIL VII: Cataract Surgery in Ebola Survivors
Objective: Zaire ebolavirus is a single-stranded RNA virus associated with high morbidity and mortality. The most recent epidemic of Ebola virus disease (EVD) in West Africa resulted in over 11,000 deaths and disabling sequelae…
- Trial name
- NCT03309020
- Testing
- Cataract surgery
- Where
- Liberia
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Ebola Virus
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02314923
- Testing
- V920 Vaccine
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Infection
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Background: Ebola is a viral infection that can spread quickly and causes life-threatening disease. Right now there is an Ebola outbreak in many countries in West Africa. There are no approved treatments for Ebola.
- Trial name
- NCT02363322
- Testing
- B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
- Where
- 11 sites in United States, Guinea and 2 more
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3…
- Trial name
- NCT04228783
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.
- Trial name
- NCT04711356
- Testing
- Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
- Where
- Sierra Leone
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Hemorrhagic Fever, Ebola
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will evaluate Convalescent Plasma (CP) added to standardized supportive care (SC) in patients with confirmed Ebola Virus Disease (EVD).
- Trial name
- Ebola-Tx (NCT02342171)
- Testing
- Convalescent Plasma
- Where
- Guinea
- Volunteers
- 606 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Prevention of Ebola Infection
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults.
- Trial name
- NCT02503202
- Testing
- V920 Consistency Lot A, V920 Consistency Lot B, V920 Consistency Lot C
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
- Trial name
- NCT02548078
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
- Where
- 2 sites in Mali, Senegal
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebolavirus Disease
VSV-ZEBOV Geneva Vaccine Trial
The hemorrhagic fever resulting from Ebola infection is frequently fatal; the current Ebola outbreak, still in its ascendant phase, has a mortality rate over 50%. There is no proven therapy or prevention available at this time.
- Trial name
- VSV-ZEBOV (NCT02287480)
- Testing
- VSV-ZEBOV
- Where
- Switzerland
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Ebola Virus
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
RV 508 was a Phase I, open-label, dose-escalation study to examine the safety, tolerability and immunogenicity of an investigational Ebola vaccine in healthy adults.
- Trial name
- NCT04041570
- Testing
- cAd3-EBO S vaccine
- Where
- Uganda
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z.
- Trial name
- NCT02485912
- Testing
- ChAd3-EBO Z, MVA-EBO Z
- Where
- Senegal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Viruses
Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Zaire ebolavirus (ZEBOV) has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02280408
- Testing
- V920
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001.
- Trial name
- NCT02269423
- Testing
- V920
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola
A Study of a New Vaccine Against Two Types of Ebola
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species…
- Trial name
- NCT05079750
- Testing
- ChAdOx1 biEBOV
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices.
- Trial name
- NCT03031912
- Testing
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
- Where
- Canada
- Volunteers
- 251 people
- Sponsor
- Canadian Immunization Research Network
Hemorrhagic Fever, Ebola
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
The 2014 outbreak of Ebola in West Africa is the largest in recorded history with widespread and intense transmission in Guinea, Liberia, and Sierra Leone.
- Trial name
- STRIVE (NCT02378753)
- Testing
- rVSVΔG-ZEBOV
- Where
- 5 sites in Sierra Leone
- Volunteers
- 8,651 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Ebola Virus
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give.
- Trial name
- NCT03719586
- Testing
- ZMapp, Remdesivir, MAb114
- Where
- 2 sites in United States, Democratic Republic of the Congo
- Volunteers
- 681 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Adult Immune Responses to Vaccine
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Background: Ebola is a virus that has infected and killed people mostly in West Africa. There is no treatment or prevention for it, but several drugs are being studied.
- Trial name
- NCT03478891
- Testing
- VRC-EBOMAB092-00-AB (MAb114)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)